Online adaptive stereotactic body radiotherapy for localized prostate cancer in patients with lower urinary tract symptoms and/or prostate hyperplasia (X-SMILE)

Stereotactic body radiotherapy (SBRT) for localized prostate cancer offers non-inferior oncological outcomes and toxicity profiles compared to conventionally or moderately hypofractioned radiotherapy regimens, with shorter treatment durations. However, SBRT may not be suitable for all patients, part...

Full description

Saved in:
Bibliographic Details
Main Authors: Kroese, Tiuri (Author) , Andratschke, Nicolaus (Author) , Belka, Claus (Author) , Corradini, Stefanie (Author) , Marschner, Sebastian (Author) , Liermann, Jakob (Author) , Hörner-Rieber, Juliane (Author) , Fink, Christoph Andreas (Author) , Debus, Jürgen (Author) , Silvia, Fabiano (Author) , Tanadini-Lang, Stephanie (Author) , Pouymayou, Bertrand (Author) , Mencarelli, Alessandro (Author) , Fesslmeier, Debra (Author) , Schiess, Antonia (Author) , Guckenberger, Matthias (Author) , Mayinger, Michael (Author)
Format: Article (Journal)
Language:English
Published: 28 May 2025
In: Radiation oncology
Year: 2025, Volume: 20, Pages: 1-11
ISSN:1748-717X
DOI:10.1186/s13014-025-02653-4
Online Access:Resolving-System, kostenfrei, Volltext: https://doi.org/10.1186/s13014-025-02653-4
Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1186/s13014-025-02653-4
Get full text
Author Notes:Tiuri Kroese, Nicolaus Andratschke, Claus Belka, Stefanie Corradini, Sebastian Marschner, Jakob Liermann, Juliane Hörner-Rieber, Christoph Fink, Jürgen Debus, Fabiano Silvia, Stephanie Tanadini-Lang, Bertrand Pouymayou, Alessandro Mencarelli, Debra Fesslmeier, Antonia Schiess, Matthias Guckenberger and Michael Mayinger
Description
Summary:Stereotactic body radiotherapy (SBRT) for localized prostate cancer offers non-inferior oncological outcomes and toxicity profiles compared to conventionally or moderately hypofractioned radiotherapy regimens, with shorter treatment durations. However, SBRT may not be suitable for all patients, particularly those with lower urogenital tract symptoms and/or prostatic hyperplasia.
Item Description:Gesehen am 24.03.2026
Physical Description:Online Resource
ISSN:1748-717X
DOI:10.1186/s13014-025-02653-4